Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

Apr. 23, 2025 — A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

The likelihood of antiviral prescribing and dispensing among patients with influenza varied by care setting, patient age, and underlying medical conditions.

Apr. 22, 2025 — A multi-state study reveals that many high-risk adults diagnosed with influenza (flu) in emergency departments and urgent care centers are not receiving timely antiviral treatment.

Trump’s new COVID-19 website features five arguments supporting the lab. Among them was the explanation that Wuhan – the Chinese city where the virus first began spreading – is home to a ...

New research shows cumin extract can prevent flu virus infection in lab cells. It works by stopping the virus from attaching ...